OKYO Pharma
OKYO
1 hedge funds and large institutions have $33.3K invested in OKYO Pharma in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
132% more capital invested
Capital invested by funds: $14.4K → $33.3K (+$18.9K)
0% more funds holding
Funds holding: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$41.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$14.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Goldman Sachs
New York
| $33.3K | +$41.9K | +19,807 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| – | -$14.4K | -7,523 | Closed |
|
OKYO Hedge Fund Activity: Q1 2023 in Review
1 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q1 2023, worth a combined $33.3K — up 132% from $14.4K a quarter earlier.
Fund positioning in OKYO was balanced in Q1 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $41.9K. The largest seller was UBS Group, exiting entirely with an estimated $14.4K sold.
- 1 institutional investor held OKYO Pharma (OKYO) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $33.3K of OKYO Pharma stock for Q1 2023, up 132% quarter-over-quarter.
- 1 fund opened new OKYO Pharma positions in Q1 2023 and 1 closed out, a net change of 0 holders.
- The largest OKYO Pharma buyer in Q1 2023 was Goldman Sachs, an estimated $41.9K added.
- The largest OKYO Pharma seller in Q1 2023 was UBS Group, an estimated $14.4K sold.
Based on aggregated 13F filings for Q1 2023.